My project aims at producing a reproducible mouse model for T2DM and its related microvascular complications to aid in studying their interrelation, and combination therapy. The disease will be induced via STZ administration using different dosage protocols and the C57Bl/6 mice will be monitored over 12-16 weeks. Can you provide tips as to how I can assess and validate the development and presence of the complications (i.e., nephropathy, neuropathy, cardiomyopathy, retinopathy, and foot ulcers) through both intrusive and non-intrusive methods?